Press Release | Newsroom | Medtronic | Medtronic to Unveil Data Supporting Endovascular Treatments for Aortic Disease at VEITHsymposium 2016

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Medtronic to Unveil Data Supporting Endovascular Treatments for Aortic Disease at VEITHsymposium 2016

DUBLIN - Nov. 14, 2016 - Medtronic plc (NYSE: MDT) today announced notable presentations of clinical studies on how endovascular treatments are furthering the treatment of core and complex aortic disease at the 43rd Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in New York from November 14 - 19, 2016.

This year, Medtronic's aortic technologies will be featured in more than 30 presentations at VEITHsymposium, including new data from the ENGAGE Global Registry, the ANCHOR registry and on the Valiant(TM) Captivia(TM) system to treat dissections. Additional presentations highlighting investigational technology from Medtronic, including the Valiant(TM) Mona LSA(TM), Valiant(TM)EVO thoracic stent graft system, Valiant® TAAA stent graft system and the Valiant ascending stent graft will occur throughout the symposium. A presentation on the chimney technique for endovascular aortic repair (ChEVAR) will also take place and include data from the PROTAGORAS study. This publication looked at a standardized use of the Endurant(TM) II/IIs stent graft system with ChEVAR.*

"Medtronic's Aortic business collaborates closely with physicians to provide meaningful clinical data to advance treatments for aortic disease," said Daveen Chopra, vice president and general manager of the Aortic business in Medtronic's Aortic & Peripheral Vascular division. "The breadth of data being presented at VEITHsymposium is further proof of our investment in innovation for the endovascular treatment of complex aortic disease."  

Notably, new sub-set analyses from the ENGAGE Global Registry will be unveiled on Tuesday, November 15 in several sessions focused on the benefits of endovascular aortic repair (EVAR) in patients with hostile necks. In these sessions, Prof. Hence Verhagen, M.D., Ph.D., chief of vascular surgery at Erasmus Medical Center in Rotterdam, the Netherlands will present a new analysis on the safety and durability of EVAR in hostile necks, and make a second presentation on long-term outcomes in patients with complex anatomies, such as angled necks, conical necks and necks with circumferential thrombus/calcium. A complementary presentation by Prof. Dittmar Böckler, M.D., University of Heidelberg, Department of Vascular Surgery in Germany will highlight data first presented at Charing Cross on the benefit of new generation EVAR devices over first generation EVAR devices.

Another key set of presentations on Thursday, November 17 will include new findings from Medtronic's ANCHOR registry - a global, multi-center, multi-arm, prospective, post-market registry evaluating the real-world applicability of the Heli-FX(TM) EndoAnchor(TM) system in up to 2,000 patients. In a series of three presentations, researchers will present new data on the use of EndoAnchor implants in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those who have hostile characteristics.

A schedule of key presentations appears below in chronological order in Eastern Standard Time.  Some of the titles included in the presentations below may include investigational devices or uses.

Tuesday, November 15

  • 7:15 a.m.- Are Advantages Of Lower AAA Related Mortality from EVAR vs. Open Repair Sustained Better with New Generation Devices: A Critical Comparison of EVAR 1 vs. the ENGAGE Registry
    • Session 9: Grand Ballroom West, 3rd Floor
    • Dittmar Boeckler, M.D.
  • 7:32a.m.: Progress with Ascending Aortic Endograft Treatment: What Lesions, Indications, Techniques, and Results
    • Session 1: Grand Ballroom East, 3rd Floor
    • Rodney A. White, M.D. / Carlos E. Donayre, M.D.
  • 7:39 a.m.: How are Long-Term EVAR Outcomes Impacted by Extremely Angled Necks, Conical Necks, and Necks with Circumferential Thrombus
    • Session 9: Grand Ballroom West, 3rd Floor
    • Hence J.M. Verhagen, M.D., Ph.D.
  • 8:26 a.m.: Update on Mona LSA Single Branched Graft for Revascularization of the Left Subclavian Artery with TEVAR: Advantages and Results
    • Session 2: Grand Ballroom East, 3rd Floor
    • Frank R. Arko, M.D. / Eric E. Roselli, M.D.
  • 10:38 a.m.: When Can Standard EVAR be Safely and Durably Performed in Patients with Hostile Necks
    • Session 12: Grand Ballroom West, 3rd Floor
    • Hence J.M. Verhagen, M.D., Ph.D.
  • 10:50 a.m.: In Most Patients with Hostile Necks Chimney EVAR (ChEVAR) is the Best Treatment: What are the Exceptions
    • Session 12: Grand Ballroom West, 3rd Floor
    • Giovanni Torsello, M.D. / Konstantinos P. Donas, M.D. / Jason T. Lee, M.D. 

Thursday, November 17, 2016

  • 11:42 a.m.: The New Valiant EVO Device for TEVAR: What Makes it Better and Early Clinical Results
    • Session 58: Grand Ballroom West, 3rd Floor
    • Ali Azizzadeh, M.D.
  • 3:36 p.m.: Long-Term (>4 Years) Results of EndoAnchors in Minimizing EVAR Failures in Hostile Aortic Necks: The ANCHOR Registry
    • Session 61: Grand Ballroom West, 3rd Floor
    • William D. Jordan, Jr., M.D. / Jean-Paul de Vries, M.D., Ph.D.
  • 3:42 p.m.: In Patients with Hostile Neck Anatomy EndoAnchors Prevent Endoleaks and Migration: A Propensity Matched Comparison of EVAR in Hostile Neck Patient with and without EndoAnchors
    • Session 61: Grand Ballroom West, 3rd Floor
    • Bart E. Muhs, M.D., Ph.D.
  • 4:06 p.m.: Can AAA Neck Dilatation After EVAR with Self-Expanding Endografts be Prevented by EndoAnchors
    • Session 61: Grand Ballroom West, 3rd Floor
    • Apostolos K. Tassiopoulos, M.D. 

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

* In the U.S., the Endurant II/IIs stent system is approved for neck lengths >=10 mm and <=60° infra-renal angulation and it is not approved for use in chEVAR procedures .

About VEITHsymposium
Now in its 43rd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Press will receive complimentary registration. Please visit or contact Pauline T. Mayer at +1-561-316-3330.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.



Krystin Hayward
Public Relations

Ryan Weispfenning
Investor Relations